全球结直肠癌治疗市场 – 行业趋势及 2030 年预测

结直肠癌治疗市场分析及规模

当今世界，严重且危及生命的疾病越来越普遍。结直肠癌就是其中一种严重疾病，全球发病率持续增长。根据世界卫生组织 (WHO) 的数据，预计到 2030 年，全球结直肠癌病例将增加约 70%。基因突变疾病的增多和不健康生活方式的增多增加了罹患结直肠癌的风险，这也推动了市场的增长。

 Data Bridge Market Research 分析了 2023-2030 年预测期内结直肠癌治疗市场的增长率。在上述预测期内，结直肠癌治疗市场的预期复合年增长率趋于 4% 左右。2022 年市场价值为 190 亿美元，到 2030 年将增长至 260 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

结直肠癌治疗市场范围和细分

Market Definition

Colorectal cancer treatment involves a varied number of drugs that are responsible for the treatment of colorectal cancer. Colorectal cancer primarily affects the older adults however it can affect any age groups. Signs and symptoms related with the colorectal cancer are weight loss, weakness, abdominal discomfort, fatigue, pain, persistent change in the bowel habits including diarrhea and constipation, cramps, rectal bleeding, blood in the stools and others.

Colorectal Cancer Treatment Market Dynamics

Drivers

• Increasing Prevalence of Cancer

As per American Cancer Society, men tend to have a 1 in 23 lifetime risk of having colorectal cancer, whereas women have a 1 in 25. Women are at a moderately lower risk than men. Colorectal cancer is the third most frequent cancer in men and the second most common cancer in women. More than 1.8 million new cases were witnessed in 2018. People surviving with localized stage colorectal cancer tend to have a 90% chance of surviving after five years. About 39% of cases are diagnosed at this early stage. The 5-year survival rate is 71% if cancer ranges to neighbouring tissues, organs, or regional lymph nodes. Thus, this factor boost the market growth.

• Rising Healthcare Expenditure And Government Support

With the growing pervasiveness of cancer, the increasing awareness for the disease and the associated treatment is also rising. Government initiatives tend to provide better and more affordable treatments along with favourable reimbursement policies which are anticipated to boost the industry growth. Additionally, growing acceptance of advanced therapies such as Erbitux (cetuximab), Avastin (bevacizumab), and Stivarga (regorafenib) is estimated to drive the market. Amgen and Allergan’s Mvasi was the first biosimilar to Avastin which was approved in U.S. and Europe, therefore marking the entry of biosimilars in the sector of oncology. Numerous other bevacizumab and cetuximab biosimilars are under development and most likely to impact branded sales when launched.

Opportunities

• Developments in the Emerging Markets

Several market players primarily focus on developing markets such as Singapore and China as they have many colorectal cancer patients and increasing medical tourism. According to the Australian Institute of Health and Welfare, more than 15,540 new cases of colorectal cancer were diagnosed in 2021. Furthermore, according to the Malaysia Healthcare Travel Council, in 2019, more than 1.22 million healthcare travelers visited Malaysia for healthcare purposes. Furthermore, the decreasing cost of treatment and involvement of advanced technologies to provide less waiting time for several procedures are most likely to boost the number of surgeries. This as a result, increases the demand for the market.

• Increasing Options of Diagnostic Techniques

There are varied diagnostic techniques that boost the growth of the market. Fecal occult blood testing (FOBT) is the most extensively prescribed screening test for CRC since it is simple, non-invasive, and has been showed to decrease the chances of death because of CRC. For instance, Clinical Genomics Technologies Pty Ltd provides InSure ONE (Fecal Immunochemical testing) for identifying blood in the stool, which helps to diagnose CRC.

 Restraints/Challenges

• High Cost of Treatment

The growing expenditure associated with the medications impede the market growth. Several drugs and surgeries cost high, and people in the major emerging and underdeveloped countries cause the under treatment of numerous patients. This hampers the market growth.

This colorectal cancer treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the colorectal cancer treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2020, Taiho Pharmaceutical Co., Ltd. launched LONSURF which is an anticancer drug, to treat colorectal cancer patients in China. The company anticipated that Lonsurf would lead to patients and medical facilities as a pharmaceutical substitute for individuals having colorectal cancer.

Global Colorectal Cancer Treatment Market Scope

The colorectal cancer treatment market is segmented on the basis of treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Chemotherapy
• 靶向治疗
• 放射治疗
• 外科手术
• 免疫疗法
• 栓塞
• 其他的

给药途径

• 口服
• 肠外
• 其他的

最终用户

• 医院
• 家庭护理
• 专科诊所
• 其他的

分销渠道

• 医院药房
• 网上药店
• 零售药店

结直肠癌治疗市场区域分析/见解

对结直肠癌治疗市场进行了分析，并按上述治疗、给药途径、最终用户和分销渠道提供了市场规模洞察和趋势。

结直肠癌治疗市场报告涉及的主要国家 包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

由于医疗保健和研发支出不断增长，以及市场参与者对新技术或现有药物配方的投入不断增加，北美在整个预测期内一直见证着结直肠癌治疗市场的积极增长。根据美国癌症协会的记录，2017 年美国报告了 95,520 例新发结肠癌病例和 39,910 例新发直肠癌病例。由于病例不断增加，结直肠癌在美国变得越来越普遍。

亚太地区在癌症发病率高、仿制药数量众多方面占据市场主导地位。中国和印度预计将在亚太市场中扮演重要角色。这是因为这两个国家人口基数庞大，结直肠癌患者发病率不断上升。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和全球结直肠癌治疗市场份额分析

结直肠癌治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对结直肠癌治疗市场的关注有关。

结直肠癌治疗市场的主要参与者包括：

• 基因泰克公司（美国）
• Abbvie, Inc（美国）
• 诺华公司（瑞士）
• 梯瓦制药工业有限公司 (以色列)
• 辉瑞公司 (美国)
• Hikma Pharmaceuticals PLC（英国）
• Alkem Labs Ltd（印度）
• Accord Healthcare（英国）
• Zydus 集团 (印度)
• Amneal Pharmaceutical Inc.（英国）
• 礼来（美国）
• 赛诺菲（法国）
• Bausch Health Companies Inc.（加拿大）
• Almirall, SA（西班牙）
• 费森尤斯卡比美国（美国）
• Sagent Pharmaceuticals, Inc.（美国）
• Hill Dermaceuticals, Inc.（美国）
• 百时美施贵宝公司 (美国)
• 安进公司 (美国)

SKU-52891